Open AccessOUTCOMES OF ELTROMBOPAG TREATMENT AND DEVELOPMENT OF IRON DEFICIENCY IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA IN TURKEY
Author(s) -
Ayça Koca Yozgat,
Göksel Leblebisatan,
Sinan Akbayram,
Simge Çınar Özel,
Zeynep Karakaş,
Erol Erduran,
Şebnem Yılmaz,
Ülker Koçak,
Şule Ünal,
Nihal Özdemir,
Meryem Albayrak,
Emine Zengin,
Yeşim Oymak,
Özcan Bör,
Hasan Fatih Çakmaklı,
Murat Söker,
Dilek Gürlek Gökçebay,
Hüseyin Tokgöz,
Barış Malbora,
Serap Karaman,
Tiraje Çelkan,
İlgen Şaşmaz,
Neşe Yaralı,
Hale Ören,
Ayşegül Ünüvar,
Namık Özbek
Publication year - 2020
Publication title -
turkish journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.351
H-Index - 16
ISSN - 1300-7777
DOI - 10.4274/tjh.galenos.2020.2019.0380
Subject(s) - eltrombopag , medicine , immune thrombocytopenia , pediatrics , intensive care medicine , immunology , platelet
Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis, or petechiae. The thrombopoietin receptor agonist eltrombopag (EPAG) is a second-line agent used to treat chronic ITP purpura in adults and children.